@article{1bcc2d2013534834b89049a32dabe467,
title = "Patterns of joint damage in severe haemophilia A treated with prophylaxis",
author = "Rachel Goren and Eleanor Pullenayegum and Blanchette, {Victor S.} and Saunya Dover and Manuel Carcao and Israels, {Sara J.} and Anthony Chan and Rivard, {Georges E.} and MacGregor Steele and St{\'e}phanie Cloutier and Klaassen, {Robert J.} and Roona Sinha and Price, {Victoria E.} and Nicole Laferriere and Elizabeth Paradis and Wu, {John K.} and Feldman, {Brian M.}",
note = "Funding Information: The Canadian Hemophilia Primary Prophylaxis Study was initially funded by grants from the Medical Research Council of Canada/Pharmaceutical Manufacturers Association of Canada Partnership Fund and the Bayer/Canadian Blood Services/Hema‐Quebec Partnership Fund. Subsequent renewals were funded by Bayer Canada Inc. Dr. Blanchette reports having received fees for participation in Advisory Boards for Amgen, Bayer, Novo Nordisk, Pfizer, Roche and Shire and Data Monitoring Boards for Octapharma and Takeda He holds grants from Sanofi and Takeda and is the non‐remunerated Chair of the International Prophylaxis Study Group, outside the submitted work. Dr. Carcao reports having received research support from Bayer, Bioverativ/Sonafi, CSL Behring, Novo Nordisk, Octapharma, Pfizer and Shire/Takeda. He has also received honoraria for speaking/participating in advisory boards from Bayer, Bioverativ/Sonofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire/Takeda. Dr. Klaassen reports personal fees from Agios Pharmaceuticals Inc, Amgen Inc, Hoffman‐LaRoche LTD, Shire Pharma Canada ULC, Novo Nordisk Canada Inc, Octapharma AG, Takeda, and Sanofi outside the submitted work. Dr. Feldman holds a patent (2009) for the Hemophilia Joint Health Score (HJHS) 2.1 with royalties paid to The Hospital for Sick Children, Centre Hospitalier Universitaire Sainte Justine, the Regents of the University of Colorado, Karolinska Hospital and the University Medical Center Utrecht, 2009. The HJHS is available under licence by The Hospital for Sick Children. {\textcopyright} Funding Information: This study was a sub-study of the Canadian Hemophilia Primary Prophylaxis Study, a cooperative initiative undertaken by the Association of Hemophilia Clinic Directors of Canada (AHCDC). Publisher Copyright: {\textcopyright} 2021 John Wiley & Sons Ltd",
year = "2021",
month = jul,
doi = "10.1111/hae.14345",
language = "English",
volume = "27",
pages = "666--673",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "4",
}